Collaborations & Alliances

BMS, Five Prime In Immuno-oncology Alliance

Will develop Five Prime’s CSF1R antibody program, including FPA008

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb Co.and Five Prime Therapeutics, Inc.have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colonystimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase I development for immunology and oncology indications. This agreement replaces the companies’ existing clinical collaboration to evaluate the safety, tolerability and efficacy of combining BMS’ Opdivo (nivolumab...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters